Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 6/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.61 |
| ▸ | POLB | P06746 | 4/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.52 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.50 |
| ▸ | CASP6 | P55212 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.49 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8563778 | 0.86 | LMNA (0.50) | ALDH1A1HSD17B10KDM4EHPGDMEN1 | |
| SCHEMBL1520426 | 0.85 | KDM4E (0.58) | ALDH1A1HSD17B10KDM4EHPGDMEN1 | |
| SCHEMBL15880673 | 0.84 | ALDH1A1 (0.64) | ALDH1A1HSD17B10KDM4EHPGDMEN1 | |
| SCHEMBL4908605 | 0.84 | PHLPP2 (0.70) | ALDH1A1HSD17B10KDM4EHPGDMEN1 | |
| SCHEMBL4908604 | 0.84 | PHLPP2 (0.70) | ALDH1A1HSD17B10KDM4EHPGDMEN1 | |
| SCHEMBL2828647 | 0.83 | MEN1 (0.58) | ALDH1A1HSD17B10KDM4EHPGDMEN1 | |
| SCHEMBL2836625 | 0.83 | ALDH1A1 (0.62) | ALDH1A1HSD17B10KDM4EHPGDMEN1 | |
| SCHEMBL19119211 | 0.83 | POLB (0.59) | ALDH1A1HSD17B10KDM4EMEN1KMT2A | |
| SCHEMBL13614102 | 0.82 | MEN1 (0.57) | ALDH1A1HSD17B10KDM4EHPGDMEN1 | |
| SCHEMBL28650672 | 0.82 | CA2 (0.49) | ALDH1A1HSD17B10KDM4EHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188139-B2 | Heterocyclic-substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188139-B2 | Heterocyclic-substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188139-B2 | Heterocyclic-substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-7790763-B2 | Substituted phenyl methanone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790763-B2 | Substituted phenyl methanone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790763-B2 | Substituted phenyl methanone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-09-07 | — | — | US | disclosed |
| EP-1838308-B1 | [4-(HETEROARYL)PIPERAZIN-1-YL]-(2,5-SUBSTITUTED -PHENYL)METHANONE DERIVATIVES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | HOFFMANN LA ROCHE (CH) | 2010-06-30 | — | — | EP | disclosed |
| EP-1848694-B1 | HETEROCYCLIC SUBSTITUTED PHENYL METHANONES AS INHIBITORS OF THE GLYCINE TRANSPORTER 1 | HOFFMANN LA ROCHE (CH) | 2009-11-25 | — | — | EP | disclosed |
| EP-1848694-B1 | HETEROCYCLIC SUBSTITUTED PHENYL METHANONES AS INHIBITORS OF THE GLYCINE TRANSPORTER 1 | HOFFMANN LA ROCHE (CH) | 2009-11-25 | — | — | EP | disclosed |
| US-7605163-B2 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-20060167009-A1 | Monocyclic substituted phenyl methanones | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-27 | — | — | US | disclosed |
| WO-2006077026-A1 | 2, 5-DISUBSTITUTED PHENYL METHANONE DERIVATIVES AS GLYCINE TRANSPORTER 1 (GLYT-I) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRY DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-07-27 | — | — | WO | disclosed |
| US-20060160788-A1 | Substituted phenyl methanone derivatives | HOFFMANN-LA ROCHE INC. | 2006-07-20 | — | — | US | disclosed |
| WO-2006072436-A1 | [4-(HETEROARYL) PIPERAZIN-1-YL]-(2,5-SUBSTITUTED -PHENYL)METHANONE DERIVATIVES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-13 | — | — | WO | disclosed |
| WO-2006072436-A1 | [4-(HETEROARYL) PIPERAZIN-1-YL]-(2,5-SUBSTITUTED -PHENYL)METHANONE DERIVATIVES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-13 | — | — | WO | disclosed |
| EP-1656361-A1 | PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| US-20050209241-A1 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. | 2005-09-22 | — | — | US | disclosed |
| WO-2005014563-A1 | PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-17 | — | — | WO | disclosed |
| US-4935511-A | Nervous system, gastrointestinal disorders | RORER PHARMACEUTICAL CORPORATION (US) | 1990-06-19 | — | — | US | disclosed |
| US-4350692-A | CEPHALOSPORINS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1982-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209241-A1 | Benzoyl-piperazine derivatives | SLC1A2, SLC18A2, SLC6A7 | ALDH1A1 1436/4885HSD17B10 2913/4885KDM4E 2701/4885 |
| US-20060160788-A1 | Substituted phenyl methanone derivatives | SLC6A5, SLC6A1, SLC1A1 | ALDH1A1 734/4885HSD17B10 398/4885KDM4E 3640/4885 |
| US-20060167009-A1 | Monocyclic substituted phenyl methanones | SLC1A2, SULT2A1, SLC6A5 | ALDH1A1 744/4885HSD17B10 548/4885KDM4E 3122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.